Survodutide: The Glucagon/GLP-1 Dual Agonist Explained

Survodutide (developer code BI 456906) is an investigational, once-weekly injectable medication being developed by Boehringer Ingelheim and Zealand Pharma. What makes it distinct is its mechanism: it is a dual agonist that activates both the glucagon receptor and the GLP-1 receptor. That combination sets it apart from the drugs most people know. Semaglutide (Ozempic, Wegovy) targets GLP-1 alone, while tirzepatide (Mounjaro, Zepbound) targets GLP-1 and GIP — you can compare those two in our guide on [tirzepatide vs semaglutide](/blog/tirzepatide-vs-semaglutide-which-works-better-2026).

The interesting piece is the glucagon component. Glucagon is often thought of only as the hormone that raises blood sugar, but it also increases energy expenditure — in effect, it can help the body burn more calories — and supports fat metabolism in the liver. By pairing glucagon activity (to raise energy burn) with GLP-1 activity (to reduce appetite and food intake), survodutide attacks weight from two directions at once. This dual approach is part of a broader wave of next-generation obesity drugs exploring new hormone combinations, alongside agents like [retatrutide](/blog/retatrutide-triple-agonist-what-the-triumph-trials-show) and [orforglipron](/blog/orforglipron-first-oral-glp1-pill-explained).

In its phase 2 obesity trial published in the New England Journal of Medicine in 2024, survodutide produced substantial weight loss. Adults with obesity (without diabetes) were randomized to different survodutide doses or placebo. At 46 weeks, participants on the higher doses lost on average up to about 19% of their body weight, compared with a small loss on placebo. Notably, the trial used a rapid dose-escalation schedule, and weight was still declining when the study ended — suggesting the full effect might be even greater with longer treatment.

These results place survodutide in the same high-efficacy tier as the leading approved and investigational agents, though direct head-to-head comparisons haven't been done, so cross-trial numbers should be read cautiously. As with all drugs in this class, gastrointestinal side effects — nausea, vomiting, and diarrhea — were the most common and were most likely during dose escalation. The glucagon component can also modestly raise heart rate, which is being watched in ongoing trials. For context on why these drugs so often cause nausea early on, see our explainer on [GLP-1 nausea](/blog/glp1-nausea-why-it-happens-and-how-to-ease-it).

This is where survodutide's glucagon activity may give it a special edge. MASH — metabolic dysfunction-associated steatohepatitis, the more serious, inflammatory form of fatty liver disease — is closely tied to obesity and insulin resistance and is a growing cause of liver damage. Because glucagon acts directly on the liver to promote fat breakdown, a glucagon/GLP-1 dual agonist is a logical candidate for treating it.

In a separate phase 2 trial reported in 2024, survodutide significantly improved MASH — more participants achieved improvement in liver inflammation and fibrosis (scarring) markers compared with placebo, without worsening of fibrosis. This dual potential — meaningful weight loss *and* direct liver benefit — is a key reason the drug is being watched closely, since many people with obesity also have fatty liver disease. It's worth noting these are phase 2 results, which establish promise but not final proof; larger, longer phase 3 trials are needed to confirm both the liver and weight benefits and to fully characterize safety.

Survodutide is not yet approved by the FDA or other regulators and remains investigational. As of 2025 it has moved into phase 3 trials — the large, multi-year studies required before a company can seek approval — covering both obesity and MASH. Phase 3 programs typically take two to three years or more to complete, followed by regulatory review, so even in the best case a medication at this stage is usually still a few years away from pharmacy shelves, and timelines can shift based on results.

It's also important to be realistic: not every promising phase 2 drug clears phase 3. Larger trials sometimes reveal that benefits are smaller than early data suggested, or that side effects (like the heart-rate increase seen with glucagon activity) matter more at scale. So while survodutide is genuinely exciting, it belongs in the category of 'watch this space,' not 'ask your doctor today.' If you're managing weight now, the approved options remain the practical choices — our comparisons of [Wegovy vs Zepbound](/blog/wegovy-vs-zepbound-which-wins-for-weight-loss-2026) and the [Mounjaro vs Zepbound](/blog/mounjaro-vs-zepbound-same-drug-different-label-2026) labels can help you understand what's available today.

For women navigating menopause, the pipeline of next-generation obesity drugs is especially relevant, because midlife brings a shift toward visceral fat and a higher risk of insulin resistance and fatty liver disease — exactly the problems survodutide is designed to address. A drug that both reduces weight and directly improves liver fat could be a meaningful option for menopausal women, who are disproportionately affected by metabolic changes as estrogen declines. You can read more about that fat shift in our article on [GLP-1 and menopause visceral fat](/blog/glp1-menopause-visceral-fat-why-belly-fat-shifts).

That said, the same cautions apply that we'd give for any GLP-1-class drug in menopause: whatever agent you eventually use, protecting muscle and bone matters, since menopause and rapid weight loss both threaten lean mass. Adequate protein and resistance training remain essential regardless of which medication wins the race to your pharmacy. For now, survodutide is a hopeful sign that treatment is getting better and more tailored — but the fundamentals of managing weight and metabolic health in menopause haven't changed. If you're weighing your current options, a conversation with a knowledgeable provider is the best next step.